Endocrine Society’s New President-Elect; Judge Stops Compounders; New GLP-1 Benefits

The Endocrine Society elected Nanette Santoro, MD, of the University of Colorado School of Medicine in Aurora, as their next president; she will serve as president-elect for a year beginning in July 2025 and start her presidency in June 2026.

CMS is taking early steps to pressure hospitals to cease gender-affirming care for minors and also proposing to allow insurers in Affordable Care Act exchanges to limit coverage of gender-affirming care. (Fierce Healthcare, Axios)

A federal judge has barred compounding pharmacies from continuing to make copies of Eli Lilly’s weight-loss and diabetes drug tirzepatide (Zepbound, Mounjaro). (Reuters via MSN)

Falling short of expectations, Novo Nordisk said its investigational fixed-dose combination of cagrilintide and semaglutide in people with obesity or overweight and type 2 diabetes led to a 15.7% reduction in body weight after 68 weeks compared with 3.1% for those on placebo in the phase III REDEFINE 2 trial.

Meanwhile, the company announced it will sell its obesity drug semaglutide (Wegovy) directly to cash-paying patients at a discount.

In people with type 2 diabetes, use of GLP-1 receptor agonists was tied to a reduced risk of developing several hematologic cancers, especially myelodysplastic syndromes and myeloproliferative neoplasms. (JAMA Network Open)

GLP-1 drugs were also linked with better graft and patient survival in kidney transplant recipients with type 2 diabetes. (Lancet Diabetes & Endocrinology)

Untreated adult growth hormone deficiency in childhood cancer survivors was tied with several adverse outcomes including neurocognitive impairment, diminished health-related quality of life, and abnormal glucose metabolism and fat percentages. (Journal of Clinical Endocrinology & Metabolism)

Long-term insufficient sleep duration and persistent late sleep onset was tied with greater blood glucose fluctuations in a continuous glucose monitoring study of Chinese adults. (JAMA Network Open)

South Africa’s competition watchdog said it was investigating Novo Nordisk and Sanofi over possible anti-competitive practices in the insulin market. (Reuters)

Please enable JavaScript to view the

comments powered by Disqus.